Structure |
Chemical Name |
CAS |
MF |
|
LEVOCARNITINE RELATED COMPOUND A (2-プロペン-1-アミニウム, 3-カルボキシ-N,N,N-トリメチル-, クロリド) |
6538-82-5 |
C7H13ClNO2 |
|
Labetalol IMpurity A |
1391051-99-2 |
C19H23NO4 |
|
ヘキサヒドロラミプリル |
99742-35-5 |
C23H38N2O5 |
|
プロポキシフェン関連化合物B (Α-D-2-アセトキシ-4-ジメチルアミノ-1,2-ジフェニル-3-メチルブタン) |
53990-51-5 |
C21H27NO2 |
|
TINIDAZOLE RELATED COMPOUND B (20 MG) (1-(2-ETHYL-SULFONYLETHYL)-2-METHYL-4-NITROIMIDAZOLE) |
25459-12-5 |
C8H13N3O4S |
|
モノリノール酸グリセリル |
26545-74-4 |
C21H38O4 |
|
CEFUROXIME AXETIL DELTA-3-ISOMERS ((1RS,6R,7R)-1-ACETOXYETHYL 3-[(CARBAMOYLOXY)METHYL]-7-[(Z)-2-(FURAN-2-YL)-2-(METHOXYIMINO)ACETAMIDO]-8-OXO-5-THIA-1-AZABICYCLO[4.2.0]OCT-3-ENE-2- |
123458-61-7 |
C20H22N4O10S |
|
LevetiracetaM IMpurity B |
358629-47-7 |
C8H12N2O2 |
|
ビス(6-アセチルアミノヘキサン酸)亜鉛 |
70020-71-2 |
C16H28N2O6Zn |
|
OXALIPLATIN IMPURITY D |
|
|
|
Fosinopril Related Compound B |
|
|
|
Tioconazole Related Compound A (25 mg) (1-[2,4-Dichloro-beta-[(3-thenyl)-oxy]phenethyl]imidazole hydrochloride) |
61709-33-9 |
C16H15Cl3N2OS |
|
トリメトプリム関連化合物B 2,4-ジアミノピリミジン-5-イル)(3,4,5-トリメトキシフェニル)メタノン) |
30806-86-1 |
C14H16N4O4 |
|
エストラ-1,3,5(10)-トリエン-3,17β-ジオール17-ブタノアート |
18069-79-9 |
C22H30O3 |
|
Fosinopril Related Compound E |
|
|
|
Fosinopril Related Compound D |
1356353-41-7 |
C30H47NNaO7P |
|
OXYTOCIN/DESMOPRESSIN VALIDATION MIXTURE |
|
|
|
FOSCARNET IMPURITY B |
55920-24-6 |
C3H8NaO5P |
|
AMIODARONE IMPURITY D |
|
|
|
DIPHENHYDRAMINE IMPURITY A |
|
C17H21NO |
|
CHLORAMPHENICOL DISODIUM DISUCCINATE |
|
C19H20Cl2N2Na2O13-2 |
|
TRANS-EPOXYPHYTOMENADIONE |
|
|
|
70476-82-3 |
70476-82-3 |
|
|
3-[1-hydroxy-4-[4-(hydroxydiphenylMethyl)-1-piperidinyl]butyl]-alpha,alpha-diMethyl benzeneacetic acid hydrochloride |
|
C32H40ClNO4 |
|
N-(alpha,alpha,alpha-Trifluoro-m-tolyl)anthranilic acid 2-hydroxyethyl ester |
32508-98-8 |
C16H14F3NO3 |
|
5,8-ジヒドロ-8-オキソ-1,3-ジオキソロ[4,5-g]キノリン-7-カルボン酸 |
26893-27-6 |
C11H7NO5 |
|
DICLAZURIL FOR VETERINARY USE - REFERENCE SPECTRUM |
|
|
|
Fluticasone Propionate Resolution Mixture |
|
C28H35F3O6S |
|
Levothyroxine for Peak Identification |
|
|
|
Orlistat Related CoMpound E |
|
|
|
SuMatriptan Succinate Related CoMpound C |
|
|
|
ARTICAINE IMPURITY A |
1712677-79-6 |
C12H18N2O3S |
|
AMIODARONE IMPURITY E |
|
|
|
Cadmium-111Cd solution |
|
Cd |
|
Pharmaceutical glass containers (Alkali leaching and release) |
|
|
|
1-(3,4-ジクロロフェニル)-5-(1-メチルエチル)ビグアニド?塩酸塩 |
6001-93-0 |
C11H16Cl3N5 |
|
マレイン酸水素1-オクタデシル |
2424-62-6 |
C22H40O4 |
|
Vitamin D Assay System Suitability |
|
|
|
Temazepam Related Compound F (15 mg) (7-chloro-1-methyl-5-phenyl-4,5-dihydro-1H-1,4-benzodiazepine-2,3-dione) |
3294-96-0 |
C16H13ClN2O2 |
|
SuMatriptan Succinate Related IMpurities |
|
|
|
ARTICAINE IMPURITY E |
|
|
|
HEPARIN LOW-MOLECULAR-MASS FOR ASSAY BRP |
|
|
|
EUROSOIL 3 |
|
|
|
Chloroquine Related CoMpound E |
5428-61-5 |
C18H26ClN3 |
|
4-アミノ-N-(3-メチル-5-イソオキサゾリル)ベンゼンスルホンアミド |
17103-52-5 |
C10H11N3O3S |
|
FLUMAZENIL - REFERENCE SPECTRUM |
|
|
|
Rubidium-85Rb solution |
|
Rb |
|
Boric acid (isotope ratio) |
|
|
|
Cefadroxil Related CoMpound I |
147103-94-4 |
C16H17N3O5S |
|
67392-87-4 |
67392-87-4 |
|
|
RIVASTIGMINE TARTRATE R-ISOMER (エチルメチルカルバミン酸(R)-3-[1-(ジメチルアミノ)エチル]フェニル, 酒石酸水素) |
415973-05-6 |
C14H22N2O2 |
|
HYDROUS BENZOYL PEROXIDE - REFERENCE SPECTRUM |
|
|
|
HEPARIN LOW-MOLECULAR-MASS FOR CALIBRATION CRS |
|
|
|
POTASSIUM CLAVULANATE - REFERENCE SPECTRUM |
|
|
|
ESKETAMINE HYDROCHLORIDE - REFERENCE SPECTRUM |
|
|
|
Cefprozil Related CoMpound K |
|
|
|
92-54-6 |
92-54-6 |
C10H14N2 |
|
IFOSFAMIDE - REFERENCE SPECTRUM |
|
|
|
Hemoglobin HbA0 (non-glycated) |
|
|
|
Abacavir Related CoMpound D |
1443421-69-9 |
C18H21ClN10O |
|
Enrofloxacin Related CoMpound Mixture |
|
|
|
SalMeterol Related CoMpound A |
|
|
|
INTERFERON GAMMA 1 B |
98059-61-1 |
|
|
OXFENDAZOLE IMPURITY B |
|
|
|
CLOSANTEL SODIUM DIHYDRATE |
|
|
|
(R)-TIMOLOL |
|
|
|
TRICLOSAN RELATED COMPOUNDS MIXTURE A (1.2 ML/AMPULE; 3 AMPULES) |
|
|
|
Anastrozole iMpurity E |
|
|
|
CitalopraM Related CoMpound G |
|
|
|
Lithium carbonate-7Li |
|
7Li2CO3 |
|
Resin bonded glass fibreboard (thermal conductivity) |
|
|
|
Oxybutynin IMpurity C |
1199574-70-3 |
C21H29NO3 |
|
OseltaMivir IMpurity A |
1364932-19-3 |
C14H24N2O4 |
|
LaMivudine Resolution Mixture C |
|
|
|
METHYLTHIONINIUM IMPURITY A |
1231958-32-9 |
C16H18N3S+ |
|
ACECLOFENAC - REFERENCE SPECTRUM |
|
|
|
POLYGLYCERYL-3 DIISOSTEARATE |
66082-42-6 |
C45H88O9 |
|
Oxymetazoline impurity A |
|
|
|
Triprolidine Hydrochloride Z-IsoMer |
51657-91-1 |
C19H23ClN2 |
|
IFOSFAMIDE IMPURITY E |
42453-19-0 |
C5H11Cl2N |
|
PANCREAS POWDER (PROTEASE) BRP |
|
|
|
RETINOL ESTERS |
|
|
|
OXFENDAZOLE WITH IMPURITY D |
|
|
|
Platinum (isotope ratio) |
|
|
|
CeftazidiMe, Delta-3-IsoMer |
|
|
|
Abacavir Related CoMpounds Mixture |
|
|
|
Fosinopril Related CoMpound F |
|
|
|
OMeprazole Related CoMpound F and G Mixture |
|
|
|
Pyrantel Related CoMpound A |
|
|
|
ZINC-64 |
|
Zn |
|
ALLOPURINOL IMPURITY A |
|
C5H4N4O |
|
IFOSFAMIDE IMPURITY B |
241482-18-8 |
C10H24Cl2N2O7P2 |
|
Lamivudine Resolution Mixture B |
|
|
|
Vancomycin B with Monodechlorovancomycin |
|
|
|
Iron-57Fe solution |
|
Fe |
|
TRIMETHOPRIM IMPURITY B |
|
|
|
Temazepam Related Compound G (15 mg) (7-Chloro-1,4-dimethyl-5-phenyl-4,5-dihydro-1H-1,4-benzodiazepine-2,3-dione) |
93329-92-1 |
C17H15ClN2O2 |
|
ENDOTOXIN STANDARD |
|
|
|
ESTRADIOL FOR PEAK IDENTIFICATION |
|
C18H24O2 |
|
82999, 237NpO2 (V encapsulated) |
58670-16-9 |
NpO2 |